AlgaeCytes

company

About

AlgaeCytes uses a photobioreactor system and freshwater algal strains to produce high purity Omega 3 oils EPA.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
€5M
Industries
Biopharma,Biotechnology,Energy Efficiency,Industrial,Industrial Engineering,Medical
Founded date
Jan 1, 2010
Number Of Employee
11 - 50
Operating Status
Active

AlgaeCytes Limited has developed a proven innovative approach to the production of Omega 3 fatty acids, which are polyunsaturated fatty acids used in numerous bodily functions, such as controlling blood clotting and building cell membranes in the brain. Associated with many health benefits, including protection against heart disease and possibly stroke, new studies are identifying potential benefits for a wide range of conditions including cancer, inflammatory bowel disease and other auto-immune diseases such as lupus and rheumatoid arthritis.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€5M
AlgaeCytes has raised a total of €5M in funding over 2 rounds. Their latest funding was raised on Jan 14, 2022 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 14, 2022 Series Unknown €5M 1 IBG Risikokapitalfonds II GmbH & Co. KG Detail

Investors

Number of Lead Investors
Number of Investors
1
1
AlgaeCytes is funded by 1 investors. IBG Risikokapitalfonds II GmbH & Co. KG are the most recent investors.
Investor Name Lead Investor Funding Round
IBG Risikokapitalfonds II GmbH & Co. KG Yes Series Unknown